Neoadjuvant and Adjuvant Pembrolizumab in Locally Advanced Head and Neck Cancer.

By R. Uppaluri, R. I. Haddad, Y. Tao, C. Le tourneau, Nancy Y. Lee, W. Westra, R. Chernock, Makoto Tahara, Kevin J. Harrington, A. Klochikhin and 23 more. 2025

Subfields: Immunology, Oncology, Otorhinolaryngology

Citations in the corpus

• Special Issue “Pathogenesis and Treatments of Head and Neck Cancer” (2025, unknown): “Neoadjuvant and perioperative administration have shown encouraging results, including high rates of major pathological response and improved disease control, raising the possibility of reducing the intensity of adjuvant treatment and better tailoring therapy to tumor biology [21,22].”